Cargando…

Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?

OBJECTIVE: Prediction of therapy response to intravenous methylprednisolone pulses (ivMP) is crucial for thyroid-associated ophthalmopathy (TAO). Image histograms may offer sensitive imaging biomarkers for therapy effect prediction. This study aimed to investigate whether pretherapeutic, multiparame...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ping, Luo, Ban, Chen, Lang, Wang, Qiu-Xia, Yuan, Gang, Jiang, Gui-hua, Zhang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947366/ https://www.ncbi.nlm.nih.gov/pubmed/33716970 http://dx.doi.org/10.3389/fendo.2021.614536

Ejemplares similares

Histogram analysis of T2 mapping for detecting early involvement of extraocular muscles in patients with thyroid-associated ophthalmopathy
por: Liu, Ping, et al.
Publicado: (2020)

Multi-Parametric Diffusion Tensor Imaging of The Optic Nerve for Detection of Dysthyroid Optic Neuropathy in Patients With Thyroid-Associated Ophthalmopathy
por: Liu, Ping, et al.
Publicado: (2022)

Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy
por: Liu, Xiaomei, et al.
Publicado: (2016)

Treating Thyroid Associated Ophthalmopathy in Pediatric Patients
por: Dong, Tianyu, et al.
Publicado: (2022)

Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy
por: Smith, Terry J.
Publicado: (2020)

Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy
por: Lai, Kenneth K. H., et al.
Publicado: (2023)

Integrative metabolic analysis of orbital adipose/connective tissue in patients with thyroid-associated ophthalmopathy
por: Huang, Jiancheng, et al.
Publicado: (2022)

Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients
por: Li, Lan-Fang, et al.
Publicado: (2023)

Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves’ Ophthalmopathy to Parenteral Corticosteroids
por: Naselli, Adriano, et al.
Publicado: (2020)

Increased brain iron in patients with thyroid-associated ophthalmopathy: a whole-brain analysis
por: Hu, Hao, et al.
Publicado: (2023)

Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy
por: Smith, Terry J., et al.
Publicado: (2017)

Rare Co-occurrence of Ocular Myasthenia Gravis and Thyroid-Associated Orbitopathy (Ophthalmopathy) in an Individual With Hypothyroidism
por: An, Ran, et al.
Publicado: (2019)

IL-11 Is Elevated and Drives the Profibrotic Phenotype Transition of Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy
por: Wu, Pengsen, et al.
Publicado: (2022)

T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy
por: Zhai, Linhan, et al.
Publicado: (2022)

Alterations in Spontaneous Neuronal Activity and Microvascular Density of the Optic Nerve Head in Active Thyroid-Associated Ophthalmopathy
por: Zhu, Pingyi, et al.
Publicado: (2022)

Decreased macular choriocapillaris in thyroid-associated ophthalmopathy: focusing on chorioretinal folds with and without optic disc edema
por: Zeng, Peng, et al.
Publicado: (2023)

Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ophthalmopathy: a systematic review and meta-analysis
por: Hu, Yu, et al.
Publicado: (2023)

Identification of optimal feature genes in patients with thyroid associated ophthalmopathy and their relationship with immune infiltration: a bioinformatics analysis
por: Xiong, Chao, et al.
Publicado: (2023)

Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy
por: Fallahi, Poupak, et al.
Publicado: (2021)

Current insights of applying MRI in Graves’ ophthalmopathy
por: Song, Cheng, et al.
Publicado: (2022)

Bisphosphonate-Induced Acute Orbital Inflammation in a Patient With Underlying Thyroid Ophthalmopathy
por: Yu, James, et al.
Publicado: (2020)

Thyroid-associated Ophthalmopathy
por: Şahlı, Esra, et al.
Publicado: (2017)

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves's ophthalmopathy
por: Philip, Rajeev, et al.
Publicado: (2013)

Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study
por: Wang, Yueyue, et al.
Publicado: (2023)

Use of Rituximab After Orbital Decompression Surgery in Two Grave’s Ophthalmopathy Patients Progressing to Optic Neuropathy
por: Zhang, Benping, et al.
Publicado: (2020)

An Interesting Case of Euthyroid Graves’ Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies
por: Moeen, Zunera, et al.
Publicado: (2021)

Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy
por: Higashiyama, Tomoaki, et al.
Publicado: (2016)

Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves’ Ophthalmopathy
por: Wang, Yan, et al.
Publicado: (2022)

Severe Grave's Ophthalmopathy–missed for many years
por: Wani, Mohd Maqbool, et al.
Publicado: (2010)

Cytokines in Thyroid-Associated Ophthalmopathy
por: Zhang, Pengbo, et al.
Publicado: (2022)

Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
por: Le Moli, Rosario, et al.
Publicado: (2020)

Association of variant on the promoter of cluster of differentiation 74 in graves disease and graves ophthalmopathy
por: Liu, Yu-Huei, et al.
Publicado: (2020)

Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves’ Ophthalmopathy
por: Virakul, Sita, et al.
Publicado: (2021)

Graves’ Ophthalmopathy in the Setting of Primary Hypothyroidism
por: Alajmi, Sarah, et al.
Publicado: (2022)

Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves’ Ophthalmopathy by Targeting Orbital Fibroblasts
por: Yang, Shenglan, et al.
Publicado: (2022)

Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves’ Orbitopathy: A Pilot Study
por: Rymuza, Joanna, et al.
Publicado: (2022)

Microarray Data of Lacrimal Gland Implicates Dysregulated Protein Processing in Endoplasmic Reticulum in Graves’ Ophthalmopathy
por: Tu, Wenling, et al.
Publicado: (2021)

Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients
por: Ahn, Hwa Young, et al.
Publicado: (2020)

Differentiating renal cell carcinoma and oncocytoma with volumetric MRI histogram analysis
por: Akinci, Ozlem, et al.
Publicado: (2023)

Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways
por: Wei, Yi-Hsuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u6pas97fcc3vfmpt7jad61eo23